The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Open accessAbstract
Introduction We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC.Methods Randomized trials comparing immune checkpoint inhibitors against chemotherapy were identified. We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS) of the intention-to-treat population and EGFR mutation-defined subgroups. We used the fixed-effects inverse variance-weighted method to pool estimates of treatment efficacy. Statistical tests were two sided.Results In the three included studies that compared immune checkpoint inhibitors (nivolumab [n = 292], pembrolizumab [n = 691], and atezolizumab [n =144]) against docetaxel (n = 776), immune checkpoint inhibitors significantly prolonged OS over that with docetaxel overall (n = 1903, HR = 0.68, 95% CI: 0.61-0.77, p < 0.0001) and in the EGFR wild-type subgroup (n = 1362, HR = 0.66, 95% CI: 0.58-0.76, p < 0.0001) but not in the EGFR-mutant subgroup (n = 186, HR = 1.05, 95% CI: 0.70-1.55, p < 0.81; treatment-mutation interaction p = 0.03).Conclusion In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. Mechanisms of acquired resistance to first-line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second-line treatment for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, low TMB suggests comparable lack of benefit to single agent PD-1 / PD-L1 antibodies in EGFRex20ins NSCLC as in NSCLC harboring more common EGFR mutations.”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citationGainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,268
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 843
Wang, C., Chiu, L., Ju, J., Lin, Y., Fang, Y., Yang, C., & Hsu, P. (2021) · Vaccines · doi:10.3390/vaccines9101122 · Cited by 25
Saw, S. P. L., Ng, W. P., Zhou, S., Lai, G. G. Y., Tan, A. C., Ang, M., Lim, W., Kanesvaran, R., Ng, Q. S., Jain, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.012 · Cited by 25
Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma
Muthusamy, B., Raskina, K., Lofgren, K. T., Li, G., Tolba, K. A., Schwed, K., Castellanos, E. H., Huang, R. S. P., Oxnard, G. R., Schrock, A. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.027 · Cited by 25
Liu, W., Huo, G., & Chen, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10959-3 · Cited by 26
O'Kane, G. M., Barnes, T. A., & Leighl, N. B. (2018) · Current Oncology · doi:10.3747/co.25.3796 · Cited by 25
Li, J., He, Q., Xiu, Y., Khan, K. S., Weng, X., & Guan, M.-J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188551 · Cited by 25
Zhao, X., Kassaye, B., Wangmo, D., Lou, E., & Subramanian, S. (2020) · iScience · doi:10.1016/j.isci.2020.101056 · Cited by 27
Yang, C., Liao, W., Ho, C., Chen, K., Tsai, T.-H., Hsu, C., Liu, Y., Su, K., Chang, Y., Wu, C., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0088 · Cited by 25
Self-citationLi, C., Liu, J., Xie, Z., Zhu, F., Cheng, B., Liang, H., Li, J., Xiong, S., Chen, Z., Liu, Z., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920965840 · Cited by 25
Hu, W., Wang, G., Yarmus, L. B., & Wan, Y. (2020) · Cancers · doi:10.3390/cancers12092496 · Cited by 24
Bayer, P., Gatenby, R. A., McDonald, P. H., Duckett, D. R., Staňková, K., & Brown, J. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261578 · Cited by 29
Yang, H.-M., Zhu, J., Xiao, R., Liu, Y., Yu, F., Cai, L., Qiu, M., & He, F. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03030-2 · Cited by 25
Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
Tsiara, A., Liontos, M., Καπαρέλου, Μ., Zakopoulou, R., Bamias, A., & Dimopoulos, M. A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.07 · Cited by 24
Zhang, L., Bai, L., Liu, X., Liu, Y., Li, S., Liu, J., Zhang, S., Yang, C., Ren, X., & Cheng, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13370 · Cited by 24
Asghariazar, V., Kadkhodayi, M., Sarailoo, M., Jolfayi, A. G., & Baradaran, B. (2023) · Pathology, Research and Practice · doi:10.1016/j.prp.2023.154792 · Cited by 20
Suda, K., Murakami, I., Yu, H., Kim, J., Ellison, K. E., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.002 · Cited by 23
Rossi, S., Castello, A., Toschi, L., & Lopci, E. (2018) · Immunotherapy · doi:10.2217/imt-2017-0187 · Cited by 23
Tumor mutation burden and recurrent tumors in hereditary lung cancer
Hsu, Y., Chang, Y., Chang, G., Ho, B., Yuan, S., Li, Y., Zeng, J.-W., Yu, S., Li, K., Yang, P., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2120 · Cited by 23
Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
Bruno, D. S., & Dowlati, A. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.06.02 · Cited by 23
Li, M., Hou, X., Chen, J., Zhang, B., Wang, N., Han, H., & Chen, L. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.006 · Cited by 22
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
Tang, Q., Zhao, S., Zhou, N., He, J., Zu, L., Liu, T., Song, Z., Chen, J., Peng, L., & Xu, S. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5497 · Cited by 25
Kwiecień, I., Skirecki, T., Polubiec-Kownacka, M., Raniszewska, A., & Domagala-Kulawik, J. J. (2019) · Cancers · doi:10.3390/cancers11040567 · Cited by 24
Zhang, F., Huang, D., Li, T., Zhang, S., Wang, J., Zhang, Y., Wang, G., Zhao, Z., Ma, J., Wang, L., et al. (2019) · Journal of Cancer · doi:10.7150/jca.37966 · Cited by 23
Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
Zhao, C., Su, C., Li, X., & Zhou, C. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13504 · Cited by 23
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Huynh, C., Walsh, L. A., & Spicer, J. D. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-509 · Cited by 23
EGFR inhibition in NSCLC: New findings…. and opened questions?
Passiglia, F., Listì, A., Castiglia, M., Perez, A., Rizzo, S., Bazan, V., & Russo, A. D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.009 · Cited by 22
Ascierto, P. A., Daniele, B., Hammers, H. J., Hirsh, V., Kim, J. W., Licitra, L. F., Nanda, R., & Pignata, S. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1309-2 · Cited by 22
Koopman, B., Garcia, B. N. C., Kuijpers, C. C. H. J., Damhuis, R. A. M., van der Wekken, A. J., Groen, H. J. M., Schuuring, E. M. D., Willems, S. M., & van Kempen, L. C. L. T. (2021) · Cancers · doi:10.3390/cancers13143641 · Cited by 22
Wu, J., Sun, W., Yang, X., Wang, H., Liu, X., Chi, K., Zhou, L., Huang, X., Mao, L., Zhao, S., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00903-w · Cited by 22
Uehara, Y., Watanabe, K., Hakozaki, T., Yomota, M., & Hosomi, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14448 · Cited by 22
Yoshimura, A., Yamada, T., Serizawa, M., Uehara, H., Tanimura, K., Okuma, Y., Fukuda, A., Watanabe, S., Nishioka, N., Takeda, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15608 · Cited by 22
Takakuwa, O., Oguri, T., Uemura, T., Sone, K., Fukuda, S., Okayama, M., Kanemitsu, Y., Ohkubo, H., Takemura, M., Ito, Y., et al. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1349 · Cited by 22
Kim, T. J., Hong, S. A., Kim, O., Kim, S. J., Yang, J., Joung, E. K., Kang, J., & Hong, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.22582 · Cited by 22
Self-citationKOBAYASHI, K. P., Seike, M., Zou, F., Noro, R., Chiba, M., Ishikawa, A., Kunugi, S., Kubota, K., & Gemma, A. (2018) · Anticancer Research · doi:10.21873/anticanres.12281 · Cited by 21
Tan, I. T., Stinchcombe, T. E., Ready, N., Crawford, J., Datto, M., Nagy, R. J., Lanman, R. B., Gu, L., & Clarke, J. M. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.03 · Cited by 23
Gianoncelli, L., Spitaleri, G., Passaro, A., Radice, D., Fumagalli, C., Signore, E. D., Stati, V., Catania, C., Guerini‐Rocco, E., Barberis, M. C. P., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13970 · Cited by 22
Epidermal Growth Factor Receptor Mutations
McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23
Benea, C., Turner, K. A., Roseman, M., Bero, L. A., Lexchin, J., Turner, E. H., & Thombs, B. D. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01318-5 · Cited by 23
Bai, M., Wang, W., Gao, X., Wu, L., Jin, P., Wu, H., Yu, J., & Meng, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832419 · Cited by 21
Selenz, C., Compes, A., Nill, M., Borchmann, S., Odenthal, M., Florin, A., Brägelmann, J., Büttner, R., Meder, L., & Ullrich, R. T. (2022) · Cancers · doi:10.3390/cancers14163943 · Cited by 21
Kuo, C. S., Wang, C., Huang, Y., Pavlidis, S. P., Liu, C., Ko, H., Chung, F., Lin, T., Wang, C., Guo, Y., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13057 · Cited by 21
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
Listì, A., Barraco, N., Bono, M., Insalaco, L., Castellana, L., Cutaia, S., Ricciardi, M. R., Gristina, V., Bronte, E., Pantuso, G., et al. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.04 · Cited by 21
Chen, J. A., & Riess, J. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.32 · Cited by 21
Yoshida, H., Nomizo, T., Ozasa, H., Tsuji, T., Funazo, T. Y., Yasuda, Y., Ajimizu, H., Yamazoe, M., Kuninaga, K., Ogimoto, T., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.035 · Cited by 20
Qian, X., Guo, X., Li, T., Hu, W., Zhang, L., Wu, C., & Ye, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.926890 · Cited by 20
Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas
Paik, P. K., Luo, J., Ai, N., Kim, R. Y., Ahn, L. S. H., Biswas, A., Coker, C., Ma, W., Wong, P., Buonocore, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33719-6 · Cited by 20
Park, H.-R., Ahn, Y., Kim, T. M., Kim, S., Kim, S., LEE, Y. S., KIM, M., Keam, B., Kim, D.-W., & Heo, D. S. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.03.312 · Cited by 20
Ackermann, C. J., Adderley, H., Franco, A. O., Khan, A. M., Reck, M., & Califano, R. (2020) · Drugs · doi:10.1007/s40265-020-01409-6 · Cited by 20
Real-world insights into patients with advanced NSCLC and MET alterations
Bittoni, M. A., Yang, J. C., Shih, J., Peled, N., Smit, E. F., Camidge, D. R., Arasada, R. R., Oksen, D., Boutmy, E., Stroh, C., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.015 · Cited by 20
Self-citationPredictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Ushio, R., Murakami, S., & Saito, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071855 · Cited by 21
Miyauchi, E., Matsuda, T., Kiyotani, K., Low, S., Hsu, Y., Tsukita, Y., Ichinose, M., Sakurada, A., Okada, Y., Saito, R., et al. (2018) · Cancer Science · doi:10.1111/cas.13919 · Cited by 20
Kalra, A., & Rashdan, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1158417 · Cited by 19
Russo, A., Franchina, T., Ricciardi, G. R. R., Toscano, G., Schifano, S., Certo, G. L., Battaglia, A., Pantò, E., Fonti, M. S., & Adamo, V. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.007 · Cited by 19
Li, Y., Chen, Z., Wu, L., & Tao, W. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.163 · Cited by 19
Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
Ren, X., Li, Y., Nishimura, C., & Zang, X. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.009 · Cited by 19
Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer
Mata, D. A., Harries, L., Williams, E. A., Hiemenz, M., Decker, B. J., Tse, J. Y., Janovitz, T., Ferguson, D. C., Speece, I., Margolis, M. L., et al. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0313-oa · Cited by 19
Hu, J., Huang, D., Wang, Y., Li, D., Yang, X., Fu, Y. H. H., Du, N., Zhao, Y., Li, X., Ma, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975246 · Cited by 19
Wallis, C. J. D., Lawson, K. A., Butaney, M., Satkunasivam, R., Parikh, J. R., Freedland, S. J., Patel, S. P., Hamid, O., Pal, S. K., & Klaassen, Z. W. A. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa021 · Cited by 19
Kubo, S., Kobayashi, N., Somekawa, K., Hirata, M., Kamimaki, C., Aiko, H., Katakura, S., Teranishi, S., Watanabe, K., Hara, Y., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14379 · Cited by 19
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Puri, S., Shafique, M. R., & Gray, J. E. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0556-7 · Cited by 18
Uemura, T., & Hida, T. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.180 · Cited by 18
Riudavets, M., Naigeon, M., Texier, M., Dorta, M., Barlési, F., Mazières, J., Varga, A., Cassard, L., Boselli, L., Grivel, J., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.018 · Cited by 19
Wu, D., Liu, Y., Li, X., Liu, Y., Yang, Q., Liu, Y., Wu, J., Tian, C., Zeng, Y., Zhao, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01366 · Cited by 19
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 19
Hu, X., Xu, H., Xue, Q., Wen, R., Jiao, W., & Tian, K. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00387-z · Cited by 19
White, M. N., Piper‐Vallillo, A. J., Gardner, R. M., Cunanan, K. M., Neal, J. W., Das, M. S., Padda, S. K., Ramchandran, K. J., Chen, T. T., Sequist, L. V. D., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.11.001 · Cited by 18
Wang, C., Fei, K., Liu, L., Duan, J., Wang, Z., Li, S., Xu, J., Zhang, X., Tian, Y., Qu, Y., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14929 · Cited by 18
Sathish, G., Monavarshini, L. K., Sundaram, K., Sendilvelan, S., & Gomathi, K. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155104 · Cited by 18
Hayashi, H., Chiba, Y., Sakai, K., Fujita, T., Yoshioka, H., Sakai, D., Kitagawa, C., Naito, T., Takeda, K., Okamoto, I., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.012 · Cited by 17
The evolving understanding of immunoediting and the clinical impact of immune escape
McCoach, C. E., & Bivona, T. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.60 · Cited by 17
Wu, J., Sun, W., Wang, H., Huang, X., Wang, X., Jiang, W., Jia, L., Wang, P., Feng, Q. F., & Lin, D. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0209 · Cited by 17
Silva, M. D., Itchins, M., & Pavlakis, N. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.87 · Cited by 17
Yang, H., Wang, Y., Jia, Z., Wang, Y., Yang, X., Wu, P., Song, Y., Xu, H., Gu, D., Chen, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.537735 · Cited by 16
Biomarkers of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Beyond PD-L1
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Viteri, S. A., & Khosravi‐Shahi, P. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.006 · Cited by 17
The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
Crombet, T., Morales, O. S., Dy, G. K., León, K., & Dávila, A. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639745 · Cited by 18
Shao, Y., Chen, B., Ou, D., Lin, Z., Hsu, C., Wang, M. ‐., Cheng, A., & Hsu, C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14270 · Cited by 17
Facchinetti, F., Bordi, P., Leonetti, A., Buti, S., & Tiseo, M. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s124380 · Cited by 17
Lam, V. K. L., & Zhang, J. J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.05.68 · Cited by 17
Treatment of oncogene-driven non-small cell lung cancer
Kastelijn, E. A., Langen, A. J. D., & Peters, B. J. M. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000572 · Cited by 16
Wang, R.-L., Liu, Z., Wang, T., Zhang, J., Liu, J., & Zhou, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1320244 · Cited by 16
D’Aiello, A., Stiles, B. M., Ohri, N., Levy, B. P., Cohen, P. R., & Halmos, B. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.02.004 · Cited by 18
Immunotherapeutic Strategies in Non-Small-Cell Lung Cancer: The Present and the Future
Steendam, C. M. J., Dammeijer, F. F., Aerts, J. G. J. V., & Cornelissen, R. (2017) · Immunotherapy · doi:10.2217/imt-2016-0151 · Cited by 15
PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival
Liu, S., Qin, T., Jia, Y., & Li, K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00189 · Cited by 17
Role of tumor gene mutations in treatment response to immune checkpoint blockades
Wang, M., Liu, Y., Wei, X., & Wei, Y. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz006 · Cited by 16
Kawana, S., Saito, R., Miki, Y., Kimura, Y., Abe, J., Sato, I., Endo, M., Sugawara, S., & Sasano, H. (2020) · Cancer Medicine · doi:10.1002/cam4.3639 · Cited by 16
Chen, Y., Wang, P., Fu, Y., Li, Q., Tian, J., Liu, T., Lin, Z., & Ding, Z. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100369 · Cited by 16
Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
Ito, T., Nagashima, H., Akiyama, M., Utsumi, Y., Sato, H., Chiba, S., Sugai, M., Ube, K., Mori, Y., Watanabe, K., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14267 · Cited by 17
Park, J., Cho, H.-G., Park, J., Lee, G., Kim, H. S., Paeng, K., Song, S., Park, G., Ock, C., & Chae, Y. K. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.01.006 · Cited by 16
Zhu, W., Geng, Q., Peng, H., Jin, Z., Li, D., Pu, X., Wang, G., & Jiang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.802467 · Cited by 17
Cortiula, F., Ruysscher, D. D., Steens, M., Wijsman, R., van der Wekken, A. J., Alberti, M., & Hendriks, L. E. L. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.013 · Cited by 16
Antigen Targets for the Development of Immunotherapies in Leukemia
Bauer, J., Nelde, A., Bilich, T., & Walz, J. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061397 · Cited by 19
Qu, F., Zhou, Y., & Yu, W. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001242 · Cited by 16
Niknafs, N., Najjar, M., Dennehy, C., Stouras, I., & Anagnostou, V. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0824 · Cited by 16
Emerging drugs for EGFR-mutated non-small cell lung cancer
Sukrithan, V., Deng, L., Barbaro, A., & Cheng, H. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1558203 · Cited by 16
Shi, W., & Zhao, W. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001090 · Cited by 15
Non-small-cell lung cancer: how to manage RET-positive disease
Andrini, E., Mosca, M., Galvani, L., Sperandi, F., Ricciuti, B., Metro, G., & Lamberti, G. (2022) · Drugs in Context · doi:10.7573/dic.2022-1-5 · Cited by 15
Takeuchi, E., Kondo, K., Okano, Y., Kunishige, M., Kondo, Y., Kadota, N., Machida, H., Hatakeyama, N., Naruse, K., Ogino, H., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04215-7 · Cited by 15
Liu, L., Li, F., Zhao, J., Zhuo, X., Lai, J., Wang, J., Jiang, F., Xu, W., Luan, F., Lin, X., et al. (2023) · Journal of Cancer · doi:10.7150/jca.77199 · Cited by 15
Ursino, C., Mouric, C., Gros, L., Bonnefoy, N., & Faget, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170321 · Cited by 17
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
Akbay, E. A., & Kim, J. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.04 · Cited by 16
Metadata
- Authors
- Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H.
- Affiliations
- The University of Sydney (AU)
- St George Hospital (AU)
- Chinese University of Hong Kong (HK)
- National Taiwan University (TW)
- Corresponding author
- Lee, Chee Khoon
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 12
- Issue
- 2
- Pages
- 403-407
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2538232731
- Cited by
- 839
- References
- 15
- Citations by year
- 2026: 47 · 2025: 61 · 2024: 68 · 2023: 84 · 2022: 93 · 2021: 98 · 2020: 100 · 2019: 100 · 2018: 123 · 2017: 62
- FWCI
- 85.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- immune checkpoint inhibitors, EGFR-mutant non-small cell lung cancer, second-line therapy, nivolumab, pembrolizumab, atezolizumab, docetaxel, overall survival, advanced non-small cell lung cancer
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms, Mutation, Prognosis, Randomized Controlled Trials as Topic, Cell Cycle Checkpoints, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
